Matthew Kane

Thanks for sharing the knowledge, as always Pablos Holman! Anyone in VC that’s interested in an easy non- CRM solution, check out his video

2

How can founders better prep themselves for early stage VC meetings? 🤔 Bill Georges partner at AlleyCorp tells me how founders need to PREP PREP PREP ✨ Address the top button early stage: 1️⃣ What's your founder story? 2️⃣ What's your go to market strategy? 3️⃣ What your product development strategy? 4️⃣ How big do you think this can get AND over what period of time? *Understand what your VC is looking for, and really try to understand their culture* ▶ https://lnkd.in/dZvciK2w Check out the entire episode of Digital Health Heavyweights Podcast and SUBSCRIBE ON YOUTUBE 🏃‍♂️🏃‍♀️🏃‍♂️🏃‍♀️💨💨

37

🧬 This week's Austin Bio + Health Roundup highlights significant data trends, my stance on covering funding announcements, new partnerships, and action across the Texas Bio Triangle. 🧬 💰 Funding: The Way I Plan to Cover Funding Announcements You may have seen reports of a local Bio & Health startup’s funding round through an SEC report filing. While some outlets have covered this, my position is not to. I prefer to support our builders directly rather than trolling the filings for scoops. There is plenty of real investigative journalism that our city would be well served by if that is where they focused. Remember I am not a journalist and I am not the media. When the company is ready to announce their round officially, I’ll gladly shout it to the rooftops. 📊 Data Peter Walker at Carta reports that in 2017, Biopharma and Medical Devices captured just under 10% of all VC dollars. By 2023, this figure rose to 17.7%, and in Q1 2024, it reached 24%. The overarching tailwinds favor our sector and region with trends towards Bio & Health and the physical & digital intersection. Energy and hardware, two other sector blossoming in Central Texas, also saw similar share gains. 🤝 M&A and Partnerships Sensi.AI, a 24/7 senior care intelligence agent, is partnering with Caring Senior Service to deploy SensiAI’s platform in Caring’s 50 locations across the US. This partnership allows seniors a better opportunity to age gracefully in their homes. 🚩 Texas Bio Triangle BioMedSA is hosting an event called Women in Bioscience, Thursday June 20th. It’s designed to connect and empower women in the bioscience industry across Central Texas, and features Randi Brosterman Hutchens discussing "Building your Personal Board." Find the link to the event in the comments. Houston-based Lokum, a staffing solution to connect clinicians and clinical staff to health care facilities, has raised a $700K pre-seed round. Congrats Ayoade (Joy) Ademuyewo on the raise. What’s Next? #AustinNext #LifeSciences #Healthcare #Biotechnology

16

7 Comments

The results are in. Emerging managers and especially sub-$25MM funds are out-performing their larger counterparts, even in a sub-optimal market. TVPI metrics for 2017 vintage was 3.8x versus 2.7x for a $100MM+ fund. Even a 2022 vintage is seeing a 1.1x vs a 1x TVPI. I'm personally working with a top-quartile sub $50MM fund that has delivered a 1.6x TVPI from a 2020 vintage with gains of over 100% for it's LPs (and no it's not pre-seed). Another solo-GP has averaged 60x MOIC. Smaller funds are more nimble, have more skin in the game and are quicker to react. Whilst it's predominantly smaller bets at an earlier stage (i.e. more risk), it also means a larger, more diversified portfolio where it only takes 1 to 2 wins to return all the capital to LPs = earlier upside. Add to that a much more favorable cost-structure, it's a relative no-brainer. A bit like startups, this segment is in it's infancy, so I expect we'll see much more data in coming years. (P.S- as I'm seeing some fantastic new operators come to the market, and we still have so much to learn, share and exchange about emerging managers, make sure to sign-up to upcoming newsletter! I'll be sharing much more in-depth insights, fund launches and interviews with GPs and LPs to create a vibrant and meaningful community- link in comments).

9

1 Comment

The more capital you raise, the more you dilute ownership. But equity dilution isn't the only path for new founders: 💰 Venture Debt → Bridges gap between funding rounds. → Provides capital without diluting ownership as much as equity raises. → Maintains founder control with no board seats for debt providers. Revenue-Based Financing → Investors receive a percentage of monthly revenue as repayments instead of equity → Ideal for high-growth companies with predictable revenue → Offers flexibility and scales growth Founders, I'm not saying you shouldn't opt for VC-backed equity financing. Just beware of equity implications - they affect you AND your VCs. According to pre-seed VC Martin Tobias, to make 10x investment profits, a startup's valuation has to be 40x higher than the entry price. He illustrates the effects of dilution on investors below 👇 Do you agree with Martin's sentiments? Why or why not? PS 🔔 Follow me for strategies and resources for startups and VCs! Looking to raise capital? 💸https://fundingstack.com/ for VCs and investors 💸https://foundersuite.com/ for startups At only $250/month: Fundingstack gets you access to 221,000+ global investors. Or you can send me a direct message with "FREETRIAL," and I'll give you a secret access link.

103

2 Comments